However, a significant proportion of organoids derived from PDAC patients with wild-type RNF43 also remained dependent on Wnt ligands, suggesting opportunities for Porcupine inhibitors and other ligand-dependent therapeutics exist beyond RNF43 mutations in pancreatic cancers (Seino et al., 2018). This evidence concerns the gene RNF43 and pancreatic neoplasm.